WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007087637) COMPOSITIONS AND METHODS USING MATRIX METALLOPROTEINASE (MMP) INHIBITORS FOR TREATING COGNITIVE IMPAIRMENT CHARACTERIZED BY PERSISTENT OR SUSTAINED MMP EXPRESSION AND/OR ACTIVITY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/087637    International Application No.:    PCT/US2007/061167
Publication Date: 02.08.2007 International Filing Date: 26.01.2007
IPC:
C12Q 1/37 (2006.01), C12N 9/50 (2006.01)
Applicants: WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION [US/US]; 1610 NE Eastgate Boulevard, Suite 650, Pullman, Washington 99163 (US) (For All Designated States Except US).
HARDING, Joseph [US/US]; (US) (For US Only).
WRIGHT, John [US/US]; (US) (For US Only).
MEIGHAN, Peter [US/US]; (US) (For US Only).
MEIGHAN, Stala [US/US]; (US) (For US Only)
Inventors: HARDING, Joseph; (US).
WRIGHT, John; (US).
MEIGHAN, Peter; (US).
MEIGHAN, Stala; (US)
Agent: ROSENMAN, Stephen, J.; Seed Intellectual Property Law Group PLLC, 701 Fifth Avenue, Suite 5400, Seattle, Washington 98104-7064 (US)
Priority Data:
60/762,388 26.01.2006 US
Title (EN) COMPOSITIONS AND METHODS USING MATRIX METALLOPROTEINASE (MMP) INHIBITORS FOR TREATING COGNITIVE IMPAIRMENT CHARACTERIZED BY PERSISTENT OR SUSTAINED MMP EXPRESSION AND/OR ACTIVITY
(FR) COMPOSITIONS ET MÉTHODES UTILISANT DES INHIBITEURS DE MÉTALLOPROTÉINASES MATRICES (MMP) POUR TRAITER DES TROUBLES COGNITIFS CARACTÉRISÉS PAR UNE EXPRESSION ET/OU UNE ACTIVITÉ PERSISTANTE OU SOUTENUE DES MÉTALLOPROTÉASES
Abstract: front page image
(EN)Particular aspects provide methods for treating cognitive impairment, comprising administration of a therapeutically effective amount of at least one matrix metalloproteinase (MMP) inhibitor sufficient to provide for at least one of precluding, alleviating, reversing, or inhibiting cognitive impairment characterized by sustained elevated expression and/or activity of at least one MMP. Persistent elevations in the expression of MMPs in the hippocampus of aged individuals have a detrimental effect on hippocampal synaptic plasticity, and are an underlying cause of cognitive deficits associated with ageing, and particular aspects therefore provide novel compositions and methods comprising use of MMP (e.g., MMP3 and/or MMP9, etc.) inhibitors to treat age-related cognitive impairment (e.g., cognitive decline). Additional embodiments comprise inhibition of MMP-3 and at least one other MMP (e.g., MMP-9, etc). Exemplary MMP inhibitors comprise a zinc-binding hydroxamate moiety (or a non-hydroxamate zinc-binding moiety), and a peptide or peptidomimetic backbone capable of binding at least one MMP.
(FR)Certains aspects particuliers ont trait à des méthodes de traitement de troubles cognitifs consistant à administrer une dose à effet thérapeutique suffisante d’au moins un inhibiteur d’une métalloprotéinase matrice (MMP) pour empêcher, soulager, inverser, ou inhiber des troubles cognitifs caractérisés par une expression et/ou une activité persistante ou soutenue d’au moins une métalloprotéase. L’élévation persistante de l’expression des MMP dans l’hippocampe de personnes âgées a un effet néfaste sur la plasticité synaptique de l’hippocampe et est la cause sous-jacente des déficits cognitifs liés au vieillissement, c’est pourquoi certains aspects portent sur de nouvelles compositions et de nouvelles méthodes utilisant des inhibiteurs des MMP (par exemple la MMP3 et la MMP9 pour traiter les troubles cognitifs, (par exemple le déclin cognitif). D’autres variantes portent sur l’inhibition de la MMP-3 et d’au moins une autre MMP (par exemple la MMP9, etc.) Des inhibiteurs donnés en exemple consistent en fragments d’hydroxamate fixant au zinc (ou un fragment non hydroxamate fixant au zinc), et un peptide ou un squelette peptidomimétique pouvant fixer au moins une MMP.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)